Key Definition
A hybridoma is an immortal cell line created by fusing a B cell with a myeloma cell. The B cell supplies the antibody specificity, while the myeloma cell provides the ability to divide indefinitely in culture. This fusion produces a single clone that produces identical monoclonal antibodies, a foundational tool in research, diagnostics, and therapy.
What Is a Hybridoma
Hybridomas are laboratory-made cells engineered to combine desirable traits from two distinct cell types. By merging a B cell, which can produce a specific antibody, with a myeloma cell, which is cancerous and capable of continuous division, researchers obtain cells that can be cultured long term while secreting a single, defined antibody. The resulting cell population is monoclonal, meaning every member produces the same antibody binding the same target epitope.
Why Fusion Is Necessary
Before hybridoma technology, obtaining large quantities of a pure antibody required harvesting them from animal sera, which yielded polyclonal mixtures recognizing multiple epitopes. B cells from immunized animals are excellent at producing specific antibodies but are short lived in culture. Myeloma cells, derived from B cell cancers, can proliferate endlessly but usually do not produce useful antibodies. Fusing these partners merges specificity with immortality, enabling the stable production of high-affinity antibodies for industry and clinical use.
B Cell Contribution
The B cell in the fusion provides the immunoglobulin genes encoding the desired antigen specificity. After immunization, B cells capable of binding a target antigen are selected and fused. These B cells carry the full genetic instructions for producing the variable regions that determine affinity and epitope recognition.
Myeloma Cell Contribution
The myeloma cell supplies the machinery for indefinite proliferation, enzyme deficiencies used for selection, and a robust cellular phenotype suited to laboratory culture. Typically, myeloma cells are chosen for attributes such as reliance on hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, which enables the use of HAT medium to select fused cells.
Historical Context and Significance
Hybridoma technology was developed in 1975 by Georges Köhler, César Milstein, and Niels Kaj Jerne, earning them the Nobel Prize in Physiology or Medicine in 1984. Their method for producing monoclonal antibodies revolutionized immunology and became a cornerstone for drug discovery, diagnostics, and targeted therapies, many of which remain in clinical use decades later.
Applications Enabled by the Fusion
The hybridoma system underpins many monoclonal antibody products and research reagents. It supports applications in diagnostics, such as pregnancy tests and pathogen detection, as well as therapeutic antibodies for cancer, autoimmune diseases, and infectious diseases. The ability to isolate a single hybridoma clone ensures batch consistency and defined binding characteristics.
Selection and Screening Process
After fusion, cells are plated in selective media that allow only fused hybridomas to survive. Clones are then screened for antibody production, specificity, and binding strength. High-producing, high-affinity clones are expanded and stored for future use, ensuring a renewable and well-characterized source of antibody.
Screening Methods
- Enzyme-linked immunosorbent assay (ELISA) for initial screening
- Flow cytometry to assess cell-surface binding
- Western blot or immunoprecipitation for specificity confirmation
- Limit dilution cloning to isolate single-cell-derived lines
Advantages and Limitations
Hybridomas offer stable, high-affinity antibody production and long-term storage capabilities. They remain a preferred platform for certain research and diagnostic workflows. However, they can present challenges related to allelic imbalance, gene rearrangements over time, and the rise of alternative platforms, such as recombinant antibody expression in cell lines or phage display libraries.
Practical Comparison
| Aspect | Details | Context |
|---|---|---|
| Fusion Partners | B cell + Myeloma cell | Combines specificity with immortality |
| Product | Monoclonal antibody | Single epitope specificity |
| Scalability | High, via culture expansion | Suitable for research and manufacturing |
| Screening Required | Yes, to identify high producers | Ensures desired binding characteristics |
| Storage | Stable frozen cell lines | Long-term repository of specific clones |
FAQ
Reader questions
What does the hybridoma produce
A hybridoma produces a monoclonal antibody specific to the antigen that originally stimulated the B cell used in the fusion.
Is the hybridoma identical to the original B cell
No. While it retains the antibody genes of the B cell, it also carries the immortal characteristics of the myeloma cell, allowing continuous division.